Gaps in pharmacological safety and regulatory oversight in the UK's Assisted Dying Bills

The proposed Assisted Dying Bills in England, Wales and Scotland bypass the usual regulatory safeguards and introduce unlicensed lethal drug protocols without the standard external oversight mechanisms.Key Messages:• The UK's proposed Assisted Dying legislation introduces lethal drug regimens without MHRA oversight, pharmacovigilance, or coroner review.• Drug combinations used for Assisted Dying are unlicensed, untested at lethal doses, and lack standardised protocols.• Political discretion over drug approval bypasses established clinical governance frameworks.• Independent regulatory oversight and structured clinical trials are urgently needed before legalisation proceeds.